BioNano Genomics: That’s impressive!
RSI for BioNano Genomics in the red
For shares, technical analysis also looks at the ratio of upward and downward movements of a price over time and records this for a period of 7 days in the Relative Strength Index. Based on this so-called RSI, Bionano Genomics is currently overbought with the value 95.38. Therefore, the classification “Sell” applies to this signal. If the relative movement is extended to 25 days (RSI25), this results in a value of 47.04 for the stock. This is considered a signal that the stock is considered neither overbought nor oversold. Accordingly, the rating on this basis is “Hold”. Overall, this results in a rating of “Sell” for the RSI.
Sentiment with buy signal
The Internet can strengthen or even turn moods. Depending on the intensity of discussion, i.e., the number of word posts on social media and the frequency and depth of the change in sentiment, new assessments for stocks emerge. In the case of Bionano Genomics, we have measured strong activity over the long term in terms of discussion intensity and assign a Buy rating to this signal. The rate of change in sentiment shows little change according to our measurement. We therefore arrive at an overall “Buy” rating for the long-term sentiment picture.
Does the share price return meet market requirements?
The stock has generated a return of -37.61 percent over the past year. Compared to stocks in the same sector (“healthcare”), this puts Bionano Genomics 63.41 percent below the average (25.8 percent). The median annual return for securities in the same sector “Life Sciences Tools and Services” is 26.21 percent. Bionano Genomics is currently 63.82 percent below this figure. Due to the underperformance, we rate the stock an overall “Sell” at this level.
Investors give thumbs up
A look at the discussion on social media shows the following pictureMarket participants were basically mostly positive about Bionano Genomics in recent days. There were a total of eight positive days and five negative days. On one day, there was no clear direction. The latest news about the company in the past one or two days is also mainly positive. Based on our sentiment analysis, Bionano Genomics therefore receives a “buy” rating. Overall, Bionano Genomics receives a “buy” rating from our editors for investor sentiment.
BioNano Genomics a Buy According to Chart Analysis
From the last 200 trading days, the average closing price for Bionano Genomics stock is calculated to be $2.05. The closing price on the last trading day was USD 2.22 (+8.29 percent difference) and we therefore assign a “buy” rating from a chart perspective. In addition to the 200-day moving average, the 50-day moving average is also often analyzed as part of the chart technique. This is currently USD 2.19, so the last closing price is at a similar level (+1.37 percent). This means that on this shorter-term analysis basis, a different rating for Bionano Genomics emerges, with the stock receiving a “hold” rating. Bionano Genomics thus receives an overall “buy” rating for simple charting purposes.